The KU Leuven spinout has completed another tranche of funding for its series B round featuring investments from the university.

Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.

GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.

Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.

Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.

Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.

The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.

The Institute for Neurophysiopathology spinout has completed a series D round.

University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.